- Home
- NRGV vs THRD Comparison
NRGV vs THRD Comparison
Compare NRGV & THRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRGV
- THRD
- Stock Information
- Founded
- NRGV 2017
- THRD 2019
- Country
- NRGV United States
- THRD United States
- Employees
- NRGV N/A
- THRD N/A
- Industry
- NRGV Industrial Machinery/Components
- THRD Biotechnology: Pharmaceutical Preparations
- Sector
- NRGV Miscellaneous
- THRD Health Care
- Exchange
- NRGV Nasdaq
- THRD Nasdaq
- Market Cap
- NRGV 190.1M
- THRD 164.2M
- IPO Year
- NRGV N/A
- THRD 2022
- Fundamental
- Price
- NRGV $0.65
- THRD $5.16
- Analyst Decision
- NRGV Buy
- THRD Hold
- Analyst Count
- NRGV 4
- THRD 3
- Target Price
- NRGV $1.94
- THRD $5.00
- AVG Volume (30 Days)
- NRGV 2.0M
- THRD 1.1M
- Earning Date
- NRGV 05-07-2025
- THRD 05-14-2025
- Dividend Yield
- NRGV N/A
- THRD N/A
- EPS Growth
- NRGV N/A
- THRD N/A
- EPS
- NRGV N/A
- THRD N/A
- Revenue
- NRGV $46,199,000.00
- THRD N/A
- Revenue This Year
- NRGV $416.66
- THRD N/A
- Revenue Next Year
- NRGV $44.89
- THRD N/A
- P/E Ratio
- NRGV N/A
- THRD N/A
- Revenue Growth
- NRGV N/A
- THRD N/A
- 52 Week Low
- NRGV $0.63
- THRD $3.18
- 52 Week High
- NRGV $2.70
- THRD $16.94
- Technical
- Relative Strength Index (RSI)
- NRGV 35.45
- THRD 80.42
- Support Level
- NRGV $0.65
- THRD $3.30
- Resistance Level
- NRGV $0.75
- THRD $5.15
- Average True Range (ATR)
- NRGV 0.11
- THRD 0.16
- MACD
- NRGV 0.02
- THRD 0.24
- Stochastic Oscillator
- NRGV 8.04
- THRD 99.47
About NRGV Energy Vault Holdings Inc.
Energy Vault Holdings Inc is a grid-scale energy storage company that is driving a faster transition to renewable power by solving the intermittence issues that are inherent to the prevalent sources of renewable energy, solar and wind. Geographical presence in United States, China and Other. Majority of its revenue comes from U.S.
About THRD Third Harmonic Bio Inc.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.